DOCSLIB.ORG

Potency Price List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Potency Price List Potency List Published 06.02.2021 # of Actives Turnaround Time (in business days) Tested Standard Rush* Super Rush 1-3 See Table Below See Table Below See Table Below Potency 4-8 1 day/active 0.5 day/active Call for TAT 9+ Call for TAT Call for TAT Call for TAT 1-3 Add 1 Day to Table Below Add 1 Day to Table Below Add 1 Day to Table Below Potency (Cream/Gel/Ointment) 4-8 10 5 Call for TAT 9+ Call for TAT Call for TAT Call for TAT Standard Rush Super Rush Active Days Price Days Price Days Price Notes 2-Methoxyestradiol 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard 4-Aminophenol 3 $160 1 $240 0 $320 4-Aminopyridine 3 $160 1 $240 0 $320 5-Aminosalicylic Acid 3 $160 1 $240 0 $320 5-Fluorouracil 3 $260 1 $390 0 $520 5- Hydroxytryptophan 3 $160 1 $240 0 $320 5-Methyltetrahydrofolate 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard 7-Keto DHEA 3 $160 1 $240 0 $320 7-Hydroxymitragynine 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard 13C - Urea 3 $710 1 $1,065 0 $1,420 Client to provide starting material or pay for standard 6,6 D2-Glucose 3 $210 1 $315 0 $420 Acebutolol 3 $160 1 $240 0 $320 Acepromazine 3 $160 1 $240 0 $320 Acepromazine Maleate 3 $160 1 $240 0 $320 Acetaminophen 3 $160 1 $240 0 $320 Acetate 3 $160 1 $240 0 $320 Acetazolamide 3 $160 1 $240 0 $320 Acetic Acid 3 $160 1 $240 0 $320 Acetohydroxamic Acid 3 $210 1 $315 0 $420 Acetyl Glucosamine 3 $160 1 $240 0 $320 Acetyl Hexapeptide 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Acetylcholine Chloride 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Acetylcysteine 3 $160 1 $240 0 $320 Drug list may not include consumables such as columns, standards, and special handling requests. Client will be contacted prior to initial testing for approval of additional expenses. Call ARL if you have a drug not on ARL's Drug List. (800) 393-1595 Potency List Published 06.02.2021 # of Actives Turnaround Time (in business days) Tested Standard Rush* Super Rush 1-3 See Table Below See Table Below See Table Below Potency 4-8 1 day/active 0.5 day/active Call for TAT 9+ Call for TAT Call for TAT Call for TAT 1-3 Add 1 Day to Table Below Add 1 Day to Table Below Add 1 Day to Table Below Potency (Cream/Gel/Ointment) 4-8 10 5 Call for TAT 9+ Call for TAT Call for TAT Call for TAT Standard Rush Super Rush Active Days Price Days Price Days Price Notes Acetyl-D-Glucosamine 3 $160 1 $240 0 $320 Acetyl-L-Carnitine 3 $160 1 $240 0 $320 Acetyl-L-Cysteine 3 $160 1 $240 0 $320 Acetylsalicylic Acid 3 $160 1 $240 0 $320 Acid Alcohol 10 $360 7 $540 4 $720 Acitretin 3 $160 1 $240 0 $320 Actinomycin D 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Acyclovir 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Adapalene 3 $260 1 $390 0 $520 Client to provide starting material or pay for standard Adenine HCl 3 $160 1 $240 0 $320 Adenosine 3 $160 1 $240 0 $320 Client must indicate if the sample is Adenosine free base or phosphate Adenosine Monophosphate 3 $160 1 $240 0 $320 Adenosine Phosphate 3 $160 1 $240 0 $320 Adenosine Triphosphate 3 $160 1 $240 0 $320 Adenosyl 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Adenosylcobalamin 3 $160 1 $240 0 $320 Adequan 3 $210 1 $315 0 $420 Alanine 5 $360 3 $540 2 $720 Alanine-Glutamine 3 $360 1 $540 0 $720 Albendazole 3 $160 1 $240 0 $320 Albuterol 3 $210 1 $315 0 $420 Albuterol Sulfate 3 $210 1 $315 0 $420 Alcohol 10 $360 7 $540 4 $720 Drug list may not include consumables such as columns, standards, and special handling requests. Client will be contacted prior to initial testing for approval of additional expenses. Call ARL if you have a drug not on ARL's Drug List. (800) 393-1595 Potency List Published 06.02.2021 # of Actives Turnaround Time (in business days) Tested Standard Rush* Super Rush 1-3 See Table Below See Table Below See Table Below Potency 4-8 1 day/active 0.5 day/active Call for TAT 9+ Call for TAT Call for TAT Call for TAT 1-3 Add 1 Day to Table Below Add 1 Day to Table Below Add 1 Day to Table Below Potency (Cream/Gel/Ointment) 4-8 10 5 Call for TAT 9+ Call for TAT Call for TAT Call for TAT Standard Rush Super Rush Active Days Price Days Price Days Price Notes Will be tested as 2 separate drugs: Hydrochlorothiazide and Spironolactone (charges will apply for Aldactazide See Note See Note See Note See Note See Note See Note both) Aldosterone 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Alendronate 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Alendronate Sodium Trihydrate 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Alfentanil HCL 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Allantoin 3 $160 1 $240 0 $320 Allithiamine Cream 3 $160 1 $240 0 $320 Allopurinol 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Alpha-glycerylphosphorylcholine (Alpha-GPC) 3 $510 1 $765 0 $1,020 Client to provide starting material or pay for standard Alpha-Ketoisocaproic Acid 3 $160 1 $240 0 $320 Alpha Lipoic Acid 3 $160 1 $240 0 $320 Alpha Thymosin Acetate 3 $210 1 $315 0 $420 Alprazolam 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Alprostadil 3 $160 1 $240 0 $320 Cannot test concentrations less than 5 mcg/mL. Cannot Super Rush if mixed with other actives. Altrenogest 3 $160 1 $240 0 $320 Alum 3 $160 1 $240 0 $320 Client must indicate the specific type of alum (e.g. potassium alum, ammonium alum, etc.) Aluminium Chlorohydrate 3 $160 1 $240 0 $320 Aluminum 10 $160 7 $240 4 $320 Cannot test less than 0.5 ug/mL Amantadine HCl 10 $360 7 $540 4 $720 Ambroxol HCl 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Amifostine 3 $260 1 $390 0 $520 Drug list may not include consumables such as columns, standards, and special handling requests. Client will be contacted prior to initial testing for approval of additional expenses. Call ARL if you have a drug not on ARL's Drug List. (800) 393-1595 Potency List Published 06.02.2021 # of Actives Turnaround Time (in business days) Tested Standard Rush* Super Rush 1-3 See Table Below See Table Below See Table Below Potency 4-8 1 day/active 0.5 day/active Call for TAT 9+ Call for TAT Call for TAT Call for TAT 1-3 Add 1 Day to Table Below Add 1 Day to Table Below Add 1 Day to Table Below Potency (Cream/Gel/Ointment) 4-8 10 5 Call for TAT 9+ Call for TAT Call for TAT Call for TAT Standard Rush Super Rush Active Days Price Days Price Days Price Notes Amikacin 3 $260 1 $390 0 $520 Amikacin Sulfate 3 $260 1 $390 0 $520 Amiloride HCl Dihydrate 3 $160 1 $240 0 $320 Aminobenzoate Potassium 3 $160 1 $240 0 $320 Aminobutyric Acid 3 $160 1 $240 0 $320 Aminocaproic Acid 3 $160 1 $240 0 $320 Aminohippuric Acid Sodium 3 $210 1 $315 0 $420 Aminolevulinic Acid 3 $160 1 $240 0 $320 Aminolevulinic Acid HCl 3 $160 1 $240 0 $320 Aminopentamide Sulfate 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Aminophylline 3 $160 1 $240 0 $320 Aminophylline Injection (equlivalent Thoephylline) 3 $160 1 $240 0 $320 Aminopyridine 3 $160 1 $240 0 $320 Amiodarone 3 $160 1 $240 0 $320 Amiodarone HCl 3 $160 1 $240 0 $320 Amitraz 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Amitriptyline 3 $160 1 $240 0 $320 Amitriptyline HCl 3 $160 1 $240 0 $320 Amlexanox 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Amlodipine 3 $160 1 $240 0 $320 Amlodipine Besylate 3 $160 1 $240 0 $320 Ammonium Aluminum Sulfate 3 $160 1 $240 0 $320 Ammonium Chloride 10 $360 7 $540 4 $720 Drug list may not include consumables such as columns, standards, and special handling requests. Client will be contacted prior to initial testing for approval of additional expenses. Call ARL if you have a drug not on ARL's Drug List. (800) 393-1595 Potency List Published 06.02.2021 # of Actives Turnaround Time (in business days) Tested Standard Rush* Super Rush 1-3 See Table Below See Table Below See Table Below Potency 4-8 1 day/active 0.5 day/active Call for TAT 9+ Call for TAT Call for TAT Call for TAT 1-3 Add 1 Day to Table Below Add 1 Day to Table Below Add 1 Day to Table Below Potency (Cream/Gel/Ointment) 4-8 10 5 Call for TAT 9+ Call for TAT Call for TAT Call for TAT Standard Rush Super Rush Active Days Price Days Price Days Price Notes Ammonium Glycyrrhizinate 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Ammonium Molybdate 3 $160 1 $240 0 $320 Ammonium Sulfate 3 $160 1 $240 0 $320 Ammonium Tetrathiomolybdate 10 $160 7 $240 4 $320 Amodiaquine HCl 3 $160 1 $240 0 $320 Amoxicillin 3 $160 1 $240 0 $320 Amoxicillin Trihydrate 3 $160 1 $240 0 $320 Amphetamine 10 $260 7 $390 4 $520 Amphetamine Sulfate 10 $260 7 $390 4 $520 Ampho-B 3 $210 1 $315 0 $420 Amphotericin B 3 $210 1 $315 0 $420 Ampicillin 3 $160 1 $240 0 $320 Anastrozole 3 $160 1 $240 0 $320 Androstenedione 3 $160 1 $240 0 $320 Angiotensin 1-7 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Anidulafungin 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard AOD-9604 Acetate 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Apomorphine 3 $160 1 $240 0 $320 Apomorphine HCl 3 $160 1 $240 0 $320 Apremilast 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Aprepitant 3 $160 1 $240 0 $320 Argatroban 3 $160 1 $240 0 $320 Arginine 3 $160 1 $240 0 $320 Drug list may not include consumables such as columns, standards, and special handling requests.
Load more

Recommended publications
  • A Simple Toxicological Analysis of Anabolic Steroid Preparations from the Black Market
    Ann Toxicol Anal. 2012; 24(2): 67-72 Available online at: c Société Française de Toxicologie Analytique 2012 www.ata-journal.org DOI: 10.1051/ata/2012011 Original article / Article original A simple toxicological analysis of anabolic steroid preparations from the black market Analyse toxicologique simple de stéroïdiens anabolisants provenant de marchés parallèles Manuela Pellegrini, Maria Concetta Rotolo, Rita Di Giovannadrea, Roberta Pacifici, Simona Pichini Department of Therapeutic Research and Medicine Evaluation, Istituto Superiore di Sanità, Via le Regina Elena 299, 00161 Rome, Italy Abstract – Objectives: A simple and rapid gas chromatography (GC) method with mass spectrometry (MS) detection was developed for the identification and quantification of anabolic steroids in pharmaceutical preparations from the black market. Material and Methods: After a liquid-liquid extraction of pharmaceutical products at acidic, neutral and basic pH with chloroform-isopropanol (9:1, v/v), the different steroids were separated by fused silica capillary column and detected by electron impact (EI)-MS in positive ionization mode. Results and Conclusion: The assay was validated in the range from 10 mg to 250 mg/g powder preparations and 0.02 mg to 200 mg/mL liquid preparations with good determination coefficients (r2 0.99) for the calibration curves. At three concentrations spanning the linear dynamic ranges of the calibration curves, mean recoveries were always higher than 90% and intra-assay and inter-assay precision and accuracy were always better than 15%. This method was successfully applied to the analysis of 15 pharmaceutical preparations sold by illegal sources. In only two cases the content was the one reported on the labels.
    [Show full text]
  • Analysis of Drugs Manual September 2019
    Drug Enforcement Administration Office of Forensic Sciences Analysis of Drugs Manual September 2019 Date Posted: 10/23/2019 Analysis of Drugs Manual Revision: 4 Issue Date: September 5, 2019 Effective Date: September 9, 2019 Approved By: Nelson A. Santos Table of Contents CHAPTER 1 – QUALITY ASSURANCE ......................................................................... 3 CHAPTER 2 – EVIDENCE ANALYSIS ......................................................................... 93 CHAPTER 3 – FIELD ASSISTANCE .......................................................................... 165 CHAPTER 4 – FINGERPRINT AND SPECIAL PROGRAMS ..................................... 179 Appendix 1A – Definitions ........................................................................................... 202 Appendix 1B – Acronyms and Abbreviations .............................................................. 211 Appendix 1C – Instrument Maintenance Schedule ..................................................... 218 Appendix 1D – Color Test Reagent Preparation and Procedures ............................... 224 Appendix 1E – Crystal and Precipitate Test Reagent Preparation and Procedures .... 241 Appendix 1F – Thin Layer Chromatography................................................................ 250 Appendix 1G – Qualitative Method Modifications ........................................................ 254 Appendix 1H – Analytical Supplies and Services ........................................................ 256 Appendix 2A – Random Sampling Procedures
    [Show full text]
  • Erteberel (LY500307) Product Data Sheet
    Product Name: Erteberel (LY500307) Revision Date: 01/10/2021 Product Data Sheet Erteberel (LY500307) Cat. No.: B1518 CAS No.: 533884-09-2 Formula: C18H18O3 M.Wt: 282.33 Synonyms: Target: Endocrinology and Hormones Pathway: Estrogen/progestogen Receptor Storage: Store at -20°C Solvent & Solubility insoluble in H2O; ≥14.1 mg/mL in DMSO; ≥48.3 mg/mL in EtOH Mass Solvent 1mg 5mg 10mg Preparing Concentration In Vitro Stock Solutions 1 mM 3.5420 mL 17.7098 mL 35.4195 mL 5 mM 0.7084 mL 3.5420 mL 7.0839 mL 10 mM 0.3542 mL 1.7710 mL 3.5420 mL Please refer to the solubility information to select the appropriate solvent. Biological Activity Shortsummary ERβ agonist, potent and selective IC₅₀ & Target Cell Viability Assay Cell Line: Human prostate cancer cell line (PC-3 cells) Preparation method： The solubility of this compound in DMSO is >10 mM. General tips for obtaining In Vitro a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months. Reacting conditions: N/A 1 | www.apexbt.com Applications: Erteberel showed potent and selective binding affinity for ERβ with EC50 value of 0.66 nM [1]. Animal experiment Animal models: Male and female rat fertility and rat and rabbit embryo-fetal development model Dosage form: 0.03 to 10 mg/kg/day for rats, or 1 to 25 mg/kg/day for rabbits, oral gavage, for 2 or 10 weeks Applications: There were no-observed adverse effect levels following LY500307 In Vivo administration of 1 mg/kg/day for male rat fertility, 0.3 mg/kg/day for female rat fertility and embryo-fetal development, and 25 mg/kg/day for rabbit embryo-fetal development [2].
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Comparative Pharmacokinetic Study of Luteolin After Oral Administration Of
    Vol. 8(16), pp. 422-428, 29 April, 2014 DOI 10.5897/AJPP2013.3835 ISSN 1996-0816 African Journal of Pharmacy and Copyright © 2014 Author(s) retain the copyright of this article Pharmacology http://www.academicjournals.org/AJPP Full Length Research Paper Comparative pharmacokinetic study of luteolin after oral administration of Chinese herb compound prescription JiMaiTong in spontaneous hypertensive rats (SHR) and Sprague Dawley (SD) rats Zhao-Huan Lou1, Su-Hong Chen2, Gui-Yuan Lv1*，Bo-Hou Xia1, Mei-Qiu Yan1, Zhi-Ru Zhang1 and Jian-Li Gao1 1Institute of Material Medica, Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou, 310053, China. 2Academy of Tradition Chinese Medicine, Wenzhou Medical University, Wenzhou 325035, China. Received 7 August, 2013; Accepted 15 April, 2014 JiMaiTong (JMT), a Chinese herb compound prescription consisted of Flos chrysanthemi Indici, Spica prunellae and Semen cassiae for anti-hypertension. Luteolin is one of the major bioactivity compositions in F. chrysanthemi Indici in JMT. There are some reports about pharmacokinetics of luteolin in extract of F. chrysanthemi and husks of peanut in normal rats, but it lacked pharmacokinetic information of luteolin residing in a Chinese herb compound prescription in hypertensive animal models. The present study aimed to develop a high-performance liquid chromatography with photodiode array detection (HPLC-DAD) method for determination of luteolin in rat plasma and for pharmacokinetic study after oral administration of JMT to spontaneous hypertensive rats (SHR) and normal Sprague Dawley (SD) rats. After oral administration of JMT to SHR and SD rats, respectively the content of luteolin in blood samples at different time points were determined by a reversed-phase high- performance liquid chromatography (RP-HPLC) coupled with liquid-liquid phase extraction.
    [Show full text]
  • Classical Recreational Drugs New Psychoactive Substances
    . Euro-DEN Plus: 2013-2017 . 23,947 presentations Classical Recreational Drugs and New Psychoactive Substances Professor Paul I Dargan Guy’s and St Thomas’ NHS Foundation Trust and King’s College London London, UK “Classical Drugs” Classification Stimulants Depressants MDMA (ecstasy) Opioids Amphetamine Benzodiazepines Cocaine GHB/GBL/1,4BD Hallucinogenics LSD Ketamine 1 Opioid Antagonist – Naloxone GHB and its Analogues GBL / 1,4BD . Competitive opioid antagonist – Onset 1-2 minutes, duration 30-90 minutes . Give in titrated 100 – 200 micrograms doses . Naloxone should be given IV – Can be given IM if no IV access . Aim to restore normal oxygenation/improve alertness . Infusion if long-acting preparation / features recur – Initial hourly dose of infusion is 2/3 of initial dose . What additional test is important in everyone with opioid toxicity? Paracetamol concentration . Ingestion of all 3 causes similar clinical features Effects of GHB / GBL Management of acute GHB/GBL toxicity 1-2mL . Mild-Moderate: – relaxation, appreciation for music & dancing, euphoria . Supportive care: ABC and monitoring – nausea, tremor, diarrhoea, agitation . Coma normally lasts 1-3 hours 3-4mL . Severe: . Airway reflexes generally well maintained – Increasing drowsiness …. coma, convulsions, respiratory depression, . Need for intubation: bradycardia – Not usually indicated if maintaining airway, no vomiting NB. Vomiting in 15-20%, convulsions in <10% . Think about dependence / risk of withdrawal in those with acute toxicity 3-6mL . Deaths: – Mostly pre-hospital, related to aspiration How many have seen a patient with this? 2 GHB Dependence/Withdrawal Acute Stimulant Toxicity . GHB: GABA-B agonist, also upregulates dopamine . Agitation and aggression, psychosis . Very frequent use: 1-2 hourly including overnight .
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma
    cells Article Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma Tamara T. Lah 1,2,3,*, Metka Novak 1, Milagros A. Pena Almidon 4, Oliviero Marinelli 4 , Barbara Žvar Baškoviˇc 1, Bernarda Majc 1,3, Mateja Mlinar 1, Roman Bošnjak 5, Barbara Breznik 1 , Roby Zomer 6 and Massimo Nabissi 4 1 Department of Genetic Toxicology and Cancer Biology, National Institute of Biology, 1000 Ljubljana, Slovenia; [email protected] (M.N.); [email protected] (B.Ž.B.); [email protected] (B.M.); [email protected] (M.M.); [email protected] (B.B.) 2 Faculty of Chemistry and Chemical Technology, University of Ljubljana, 1000 Ljubljana, Slovenia 3 Jožef Stefan International Postgraduate School, 1000 Ljubljana, Slovenia 4 School of Pharmacy, Experimental Medicine Section, University of Camerino, 62032 Camerino, Italy; [email protected] (M.A.P.A.); [email protected] (O.M.); [email protected] (M.N.) 5 Department of Neurosurgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia; [email protected] 6 MGC Pharmaceuticals d.o.o., 1000 Ljubljana, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +386-41-651-629 Simple Summary: Among primary brain tumours, glioblastoma is the most aggressive. As early relapses are unavoidable despite standard-of-care treatment, the cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) alone or in combination have been suggested as a combined treatment strategy for glioblastomas. However, the known psychoactive effects of THC hamper its medical applications in these patients with potential cognitive impairment due to the progression of the Citation: Lah, T.T.; Novak, M.; Pena Almidon, M.A.; Marinelli, O.; disease.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Effects of Androgenic-Anabolic Steroids on Apolipoproteins and Lipoprotein (A) F Hartgens, G Rietjens, H a Keizer, H Kuipers, B H R Wolffenbuttel
    253 Br J Sports Med: first published as 10.1136/bjsm.2003.000199 on 21 May 2004. Downloaded from ORIGINAL ARTICLE Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a) F Hartgens, G Rietjens, H A Keizer, H Kuipers, B H R Wolffenbuttel ............................................................................................................................... Br J Sports Med 2004;38:253–259. doi: 10.1136/bjsm.2003.000199 Objectives: To investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes. Methods: In a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2- C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined. Results: In study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l.
    [Show full text]
  • 01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except
    AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2
    [Show full text]